3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
98
Stomach Neoplasms
50
Rectal Neoplasms
45
Pancreatic Neoplasms
45
Colonic Neoplasms
36
Esophageal Neoplasms
34
Neoplasms
30
Neoplasm Metastasis
28
Squamous Cell Carcinoma of Head and Neck
27
Head and Neck Neoplasms
24
Breast Neoplasms
21
Adenocarcinoma Of Esophagus
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
12
Adenocarcinoma
9
Anus Neoplasms
8
Esophageal Squamous Cell Carcinoma
7
Carcinoma, Squamous Cell
7
Carcinoma
7
Cholangiocarcinoma
6
Liver Neoplasms
5
Gallbladder Neoplasms
5
Bile Duct Neoplasms
5
Urinary Bladder Neoplasms
4
Pancreatic Adenocarcinoma
4
Gastrointestinal Neoplasms
4
Carcinoma, Hepatocellular
4
Skin Neoplasms
3
Sarcoma
3
Peritoneal Neoplasms
3
Laryngeal Neoplasms
3
Interventions
Lenalidomide
3
Bortezomib
3
Dexamethasone
2
vandetanib
1
umbralisib
1
ublituximab
1
marizomib
1
durvalumab
1
carotuximab
1
avelumab
1
Zoledronic Acid
1
Vitamin D
1
Transplantation, Autologous
1
Tamoxifen
1
Standard of Care
1
Practice Guidelines as Topic
1
Palliative Care
1
Oxaliplatin
1
Melphalan
1
Leucovorin
1
Irinotecan
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Filgrastim
1
Cyclophosphamide
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Disease Progression
×
Fluorouracil
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts